Identification of the platelet ADP receptor targeted by antithrombotic drugs

Gunther Hollopeter, Hans-Michael Jantzen, Diana Vincent, Georgia Li, Laura England, Vanitha Ramakrishnan, Ruey-Bing Yang, Paquita Nurden, Alan Nurden, David Julius and Pamela B. Conley ()
Additional contact information
Gunther Hollopeter: University of California, San Francisco
Hans-Michael Jantzen: COR Therapeutics, Inc.
Diana Vincent: COR Therapeutics, Inc.
Georgia Li: COR Therapeutics, Inc.
Laura England: University of California, San Francisco
Vanitha Ramakrishnan: COR Therapeutics, Inc.
Ruey-Bing Yang: COR Therapeutics, Inc.
Paquita Nurden: UMR 5533 CNRS, Hôpital Cardiologique
Alan Nurden: UMR 5533 CNRS, Hôpital Cardiologique
David Julius: University of California, San Francisco
Pamela B. Conley: COR Therapeutics, Inc.

Nature, 2001, vol. 409, issue 6817, 202-207

Abstract: Abstract Platelets have a crucial role in the maintenance of normal haemostasis, and perturbations of this system can lead to pathological thrombus formation and vascular occlusion, resulting in stroke, myocardial infarction and unstable angina. ADP released from damaged vessels and red blood cells induces platelet aggregation through activation of the integrin GPIIb–IIIa and subsequent binding of fibrinogen. ADP is also secreted from platelets on activation, providing positive feedback that potentiates the actions of many platelet activators1. ADP mediates platelet aggregation through its action on two G-protein-coupled receptor subtypes2,3. The P2Y1 receptor couples to Gq and mobilizes intracellular calcium ions to mediate platelet shape change and aggregation4,5. The second ADP receptor required for aggregation (variously called P2YADP, P2YAC, P2Ycyc or P2TAC) is coupled to the inhibition of adenylyl cyclase through Gi. The molecular identity of the Gi-linked receptor is still elusive, even though it is the target of efficacious antithrombotic agents, such as ticlopidine and clopidogrel6,7,8 and AR-C66096 (ref. 9). Here we describe the cloning of this receptor, designated P2Y12, and provide evidence that a patient with a bleeding disorder10 has a defect in this gene. Cloning of the P2Y12 receptor should facilitate the development of better antiplatelet agents to treat cardiovascular diseases.

Date: 2001
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/35051599 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:nature:v:409:y:2001:i:6817:d:10.1038_35051599

Ordering information: This journal article can be ordered from
https://www.nature.com/

DOI: 10.1038/35051599

Access Statistics for this article

Nature is currently edited by Magdalena Skipper

More articles in Nature from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().